193 related articles for article (PubMed ID: 15923432)
21. Sequence-dependent antiproliferative effects of gefitinib and docetaxel on non-small cell lung cancer (NSCLC) cells and the possible mechanism.
Chen B; Zheng J; Zeng Y; Li B; Xie B; Zheng J; Zhou J; Zhang W
PLoS One; 2014; 9(12):e114074. PubMed ID: 25474307
[TBL] [Abstract][Full Text] [Related]
22. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
Vokes EE; Chu E
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
[TBL] [Abstract][Full Text] [Related]
23. Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers.
Yonesaka K; Zejnullahu K; Lindeman N; Homes AJ; Jackman DM; Zhao F; Rogers AM; Johnson BE; Jänne PA
Clin Cancer Res; 2008 Nov; 14(21):6963-73. PubMed ID: 18980991
[TBL] [Abstract][Full Text] [Related]
24. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
Wu M; Yuan Y; Pan YY; Zhang Y
Mol Med Rep; 2014 Jun; 9(6):2417-22. PubMed ID: 24682085
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.
Kelly MP; Lee ST; Lee FT; Smyth FE; Davis ID; Brechbiel MW; Scott AM
Prostate; 2009 Jan; 69(1):92-104. PubMed ID: 18942092
[TBL] [Abstract][Full Text] [Related]
26. Targeted therapies: Biomarkers in NSCLC for selecting cetuximab therapy.
Stinchcombe TE; Socinski MA
Nat Rev Clin Oncol; 2010 Aug; 7(8):426-8. PubMed ID: 20668478
[No Abstract] [Full Text] [Related]
27. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner.
Flaig TW; Su LJ; McCoach C; Li Y; Raben D; Varella-Garcia M; Bemis LT
BJU Int; 2009 Jun; 103(12):1729-37. PubMed ID: 19220256
[TBL] [Abstract][Full Text] [Related]
28. Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck.
Sharafinski ME; Ferris RL; Ferrone S; Grandis JR
Head Neck; 2010 Oct; 32(10):1412-21. PubMed ID: 20848399
[TBL] [Abstract][Full Text] [Related]
29. Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors.
Blackledge G; Averbuch S
Br J Cancer; 2004 Feb; 90(3):566-72. PubMed ID: 14760365
[TBL] [Abstract][Full Text] [Related]
30. Sequence dependence of cell growth inhibition by EGFR-tyrosine kinase inhibitor ZD1839, docetaxel, and cisplatin in head and neck cancer.
Klass CM; Choe MS; Hurwitz SJ; Tighiouart M; Zhang X; Chen ZG; Shin DM
Head Neck; 2009 Oct; 31(10):1263-73. PubMed ID: 19399750
[TBL] [Abstract][Full Text] [Related]
31. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
32. Epidermal growth factor receptor-directed therapy in esophageal cancer.
Pande AU; Iyer RV; Rani A; Maddipatla S; Yang GY; Nwogu CE; Black JD; Levea CM; Javle MM
Oncology; 2007; 73(5-6):281-9. PubMed ID: 18477853
[TBL] [Abstract][Full Text] [Related]
33. The role of cetuximab in the treatment of squamous cell cancer of the head and neck.
Burtness B
Expert Opin Biol Ther; 2005 Aug; 5(8):1085-93. PubMed ID: 16050785
[TBL] [Abstract][Full Text] [Related]
34. Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer.
Pajares B; Trigo JM; Toledo MD; Álvarez M; González-Hermoso C; Rueda A; Medina JA; de Luque V; Jerez JM; Alba E
BMC Cancer; 2013 Jan; 13():26. PubMed ID: 23331666
[TBL] [Abstract][Full Text] [Related]
35. Pingyangmycin downregulates the expression of EGFR and enhances the effects of cetuximab on esophageal cancer cells and the xenograft in athymic mice.
Gong JH; Liu XJ; Li Y; Zhen YS
Cancer Chemother Pharmacol; 2012 May; 69(5):1323-32. PubMed ID: 22311160
[TBL] [Abstract][Full Text] [Related]
36. Epidermal growth factor receptor (EGFR) inhibitors in cancer therapy.
Ciardiello F; De Vita F
Prog Drug Res; 2005; 63():93-114. PubMed ID: 16265878
[No Abstract] [Full Text] [Related]
37. Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells.
Benavente S; Huang S; Armstrong EA; Chi A; Hsu KT; Wheeler DL; Harari PM
Clin Cancer Res; 2009 Mar; 15(5):1585-92. PubMed ID: 19190133
[TBL] [Abstract][Full Text] [Related]
38. In vitro and in vivo antitumor activity of cetuximab in human gastric cancer cell lines in relation to epidermal growth factor receptor (EGFR) expression and mutational phenotype.
Hotz B; Keilholz U; Fusi A; Buhr HJ; Hotz HG
Gastric Cancer; 2012 Jul; 15(3):252-64. PubMed ID: 22011788
[TBL] [Abstract][Full Text] [Related]
39. Pharmacology of epidermal growth factor inhibitors.
Toffoli G; De Mattia E; Cecchin E; Biason P; Masier S; Corona G
Int J Biol Markers; 2007; 22(1 Suppl 4):S24-39. PubMed ID: 17520578
[TBL] [Abstract][Full Text] [Related]
40. Cetuximab: from bench to bedside.
Vincenzi B; Zoccoli A; Pantano F; Venditti O; Galluzzo S
Curr Cancer Drug Targets; 2010 Feb; 10(1):80-95. PubMed ID: 20088790
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]